

Resource Summary Report

Generated by NIF on Jul 29, 2026

APC anti-human CD45

RRID:AB_314399

Type: Antibody

Proper Citation

BioLegend Cat# 304011, RRID:AB_314399

Antibody Information

URL: http://antibodyregistry.org/AB_314399

Proper Citation: BioLegend Cat# 304011, RRID:AB_314399

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_314399

Vendor: BioLegend

Catalog Number: 304011

Alternative Catalog Numbers: 304012, 304037

Record Creation Time: 20250820T070106+0000

Record Last Update: 20250821T012525+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD45.

No alerts have been found for APC anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liang C, et al. (2025) Mutant NPM1 modulates PDCD4 ubiquitination degradation and facilitates leukemogenesis. *iScience*, 28(11), 113776.

Zhang T, et al. (2025) Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. *iScience*, 28(5), 112302.

Li T, et al. (2025) Dysregulation of apolipoprotein o reprograms CCR7+CD4+T cell fate in primary autoimmune thrombocytopenia. *iScience*, 28(11), 113792.

Cao Z, et al. (2025) Interferon-?-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer. *Cell reports. Medicine*, 6(3), 102017.

Wang W, et al. (2025) BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma. *Cell reports. Medicine*, 6(3), 101995.

Peng P, et al. (2024) Pro-survival signaling regulates lipophagy essential for multiple myeloma resistance to stress-induced death. *Cell reports*, 43(7), 114445.

Wen X, et al. (2024) RHOF activation of AKT/?-catenin signaling pathway drives acute myeloid leukemia progression and chemotherapy resistance. *iScience*, 27(7), 110221.

Emmerich K, et al. (2024) Protocol for differentiation of monocytes and macrophages from human induced pluripotent stem cells. *STAR protocols*, 5(3), 103217.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. *Cell reports. Medicine*, 5(11), 101827.

Chiffelle J, et al. (2024) Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. *Immunity*, 57(10), 2466.

Mihlan M, et al. (2024) Neutrophil trapping and nexocytosis, mast cell-mediated processes for inflammatory signal relay. *Cell*, 187(19), 5316.

Hasegawa T, et al. (2023) Cytotoxic CD4⁺ T cells eliminate senescent cells by targeting cytomegalovirus antigen. *Cell*, 186(7), 1417.

Tzioras M, et al. (2023) Human astrocytes and microglia show augmented ingestion of synapses in Alzheimer's disease via MFG-E8. *Cell reports. Medicine*, 4(9), 101175.

Chen G, et al. (2023) Derived myeloid lineage induced pluripotent stem as a platform to study human C-C chemokine receptor type 5³² homozygotes. *iScience*, 26(11), 108331.

Ragazzini R, et al. (2023) Defining the identity and the niches of epithelial stem cells with highly pleiotropic multilineage potency in the human thymus. *Developmental cell*, 58(22), 2428.

Steitz AM, et al. (2023) TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasion. *iScience*, 26(12), 108401.

Chen S, et al. (2022) Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1. *Cell metabolism*, 34(11), 1843.

Nahmgoong H, et al. (2022) Distinct properties of adipose stem cell subpopulations determine fat depot-specific characteristics. *Cell metabolism*, 34(3), 458.

Michalek S, et al. (2022) LRH-1/NR5A2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance. *EMBO reports*, 23(9), e54195.

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. *Journal of hematology & oncology*, 14(1), 142.